{"id":56,"date":"2017-03-15T08:41:21","date_gmt":"2017-03-14T23:41:21","guid":{"rendered":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/pathophysiology\/?page_id=56"},"modified":"2017-03-15T08:49:41","modified_gmt":"2017-03-14T23:49:41","slug":"2013-2","status":"publish","type":"page","link":"http:\/\/www.med.miyazaki-u.ac.jp\/home\/pathophysiology\/works\/2013-2\/","title":{"rendered":"2013"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n

\u25a0\u539f\u8457\u8ad6\u6587<\/p>\n

1. Sato Y, Benirschke K, Marutsuka K, Yano Y, Hatakeyama K, Iwakiri T,Yamada N, Kodama Y, Sameshima H, Ikenoue T, Asada Y. Associations of intrauterine growthrestriction with placental pathologicalfactors, maternal factors and fetal factors; clinicopathological findings of 257 Japanese cases. Histol Histopathol 2013; 28: 127-32.<\/p>\n

2. Nishihira K, Hatakeyama K, Shibata Y, Kitamura K, Asada Y. Organized thrombus in aspirated coronary materials can predict in-hospital mortality of patients with acute myocardial infarction. Circ J 2013; 77: 1275-80.<\/p>\n

3. Sugita C, Yamashita A, Matsuura Y, Iwakiri T, Okuyama N, Matsuda S, Matsumoto T, Inoue O, Harada A, Kitazawa T, Hattori K, Shima M, Asada Y. Elevated plasma factor VIII enhances venous thrombus formation in rabbits: Contribution of factor XI, von Willebrand factor and tissue factor. Thromb Haemost 2013; 110: 62-75.<\/p>\n

4. Yamashita A, Zhao Y, Zhao S, Matsuura Y, Sugita C, Iwakiri T, Okuyama N, Ohe K, Koshimoto C, Kawai K, Tamaki N, Kuge Y, Asada Y. Arterial (18)F-fluorodeoxyglucose uptake reflects balloon catheter-induced thrombus formation and tissue factor expression via nuclear factor-\u03bab in rabbit atherosclerotic lesions. Circ J 2013; 77: 2626-35.<\/p>\n

5. Iwakiri T, Fujimoto S, Kitagawa K, Furuichi K, Yamahana J, Matsuura Y, Yamashita A, Uezono S, Shimao Y, Hisanaga S, Tokura T, Wada T, Kitamura K, Asada Y. Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. BMC Nephrol 2013; 14: 125.<\/p>\n

6. Wang Y, Niimi M, Nishijima K, Waqar AB, Yu Y, Koike T, Kitajima S, Liu E, Inoue T, Kohashi M, Keyamura Y, Yoshikawa T, Zhang J, Ma L, Zha X, Watanabe T, Asada Y, Chen YE, Fan J. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol 2013; 33: 224-31.<\/p>\n

7. Nagata S, Hatakeyama K, Asami M, Tokashiki M, Hibino H, Nishiuchi Y, Kuwasako K, Kato J, Asada Y, Kitamura K. Big angiotensin-25: A novel glycosylated angiotensin-related peptide isolated from human urine. Biochem Biophys Res Commun 2013; 441: 757-62.<\/p>\n

8. Iwakiri T, Sato Y, Matsuura Y, Hatakeyama K, Marutsuka K, Yamashita A,Fujimoto S, Kitamura K, Asada Y. Association Between Renal Vasculature Changes and Generalized Atherosclerosis: An Autopsy Survey. J Atheroscler Thromb., 2014; 21: 99-107.<\/p>\n

9. \u6e05\u5c71\u548c\u662d\u3001\u8352\u6b66\u516b\u8d77\u3001\u767d\u6ff1\u5e78\u751f\u3001\u5bfa\u7530\u4e00\u5f25\u3001\u4f50\u85e4\u4fe1\u4e5f\u3001\u4e38\u585a\u6d69\u52a9\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u5e74\u68ee\u5553\u9686\u3001\u6817\u6797\u5fe0\u4fe1\uff1a\u7532\u72b6\u817a\u764c\u306e\u5206\u5316\u5ea6\u63a8\u5b9a\u30de\u30fc\u30ab\u30fc\u3068\u3057\u3066\u306eCD26\/DPP IV\u6d3b\u6027\u67d3\u8272\u306e\u6709\u7528\u6027. J Jpn Soc Cytol 2013; 52: 422-7.<\/p>\n

10. Ali H, Emoto N, Yagi K, Vignon-Zellweger N, Nakayama K, Hatakeyama K, Asada Y, Rikitake Y, Hirata K. Localization and characterization of a novel secrete protein, SCUBE2, in the development and progression of atherosclerosis. Kobe J Med Sci. 2013; 59: E122-31.<\/p>\n

\u25a0\u8457\u66f8<\/p>\n

1. \u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u51dd\u56fa\u30fb\u7dda\u6eb6\u7cfb\u306e\u751f\u7406\u3068\u75c5\u7406\u3001\u5fc3\u539f\u6027\u8133\u585e\u6813\u75c7\u3068\u7d4c\u53e3\u6297\u51dd\u56fa\u85ac\uff1a\u65b0\u898f\u6297\u51dd\u56fa\u85ac\u306e\u9078\u3073\u65b9\u30fb\u4f7f\u3044\u65b9\u3001pp25-30 (2013), \u8c4a\u7530\u4e00\u5247\u3000\u7de8\u3001\u30d5\u30b8\u30e1\u30c7\u30a4\u30ab\u30eb\u51fa\u7248\uff08\u5927\u962a\uff09<\/p>\n

2. \u5f8c\u85e4\u6df8\u9999\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u7b2c\uff13\u90e8\u3000\u9451\u5225\u30dd\u30a4\u30f3\u30c8\u3000III.\u4e73\u982d\u72b6\u3001\u7ba1\u72b6\u4e73\u982d\u72b6\u69cb\u7bc9\u3092\u793a\u3059\u816b\u760d\u306e\u9451\u5225\u3000\u3000\u9577\u5d8b\u6d0b\u6cbb\u30fb\u9ed2\u7530\u76f4\u4eba\u7de8\u3000\u816b\u760d\u75c5\u7406\u9451\u5225\u8a3a\u65ad\u30a2\u30c8\u30e9\u30b9\u3000\u814e\u764c\u3001\u6587\u5149\u5802\u3001pp191-194\uff082013\uff09
\n\u25a0\u7dcf\u8aac<\/p>\n

1. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u30a2\u30c6\u30ed\u30fc\u30e0\u8840\u6813\u75c7\u306e\u767a\u75c7\u75c5\u7406\u3001\u6cd5\u533b\u75c5\u7406 2013; 19: 17-22.<\/p>\n

2. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u6027\u30d7\u30e9\u30fc\u30af\u306e\u5f62\u6210\u30fb\u7834\u7dbb\u3068\u8840\u6813\u75c7\u306e\u75c5\u614b\u3001\u8840\u6813\u6b62\u8840\u8a8c 2013; 24: 5-11.<\/p>\n

3. \u5c71\u4e0b\u3000\u7be4\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u8840\u6813\u6027\u75be\u60a3\u306e\u75c5\u7406\u3068\u75c5\u614b\u3001Current Therapy 2013; 31: 246-53.<\/p>\n

4. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u51a0\u52d5\u8108\u30d7\u30e9\u30fc\u30af\u306e\u75c5\u7406\u3001Medical Science Digest 2013; 39: 162-5.<\/p>\n

5. \u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316revised-\u52d5\u8108\u786c\u5316\u3068\u7ca5\u72b6\u786c\u5316\u306e\u75c5\u7406-\u3000Heart View 2013; 17: 638-44.<\/p>\n

6. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u75c5\u7406\u5b66\u7684\u306b\u307f\u305f\u51a0\u52d5\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u6162\u6027\u708e\u75c7\u3092\u77e5\u308b\u3001Vascular Medicine 2013; 9: 13-22.<\/p>\n

7. \u5c71\u4e0b\u3000\u7be4\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u30d0\u30eb\u30fc\u30f3\u30ab\u30c6\u30fc\u30c6\u30eb\u306b\u3088\u308b\u53cd\u5fa9\u50b7\u5bb3\u8840\u6813\u30e2\u30c7\u30eb\u3001Thrombosis Medicine 2013; 3: 28-35.<\/p>\n

8. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u6025\u6027\u51a0\u75c7\u5019\u7fa4\u306e\u75c5\u7406\u3001medicina 2013; 50\uff1a 954-7.<\/p>\n

9. \u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u3068\u8840\u6813\u6027\u75be\u60a3\u306e\u95a2\u9023\uff0d\u75c5\u7406\u5b66\u7684\u898b\u5730\u304b\u3089\u3001\u52d5\u8108\u786c\u5316\u4e88\u9632 2013; 12: 5-11.<\/p>\n

10. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u6821\u3078\u306e\u708e\u75c7\u306e\u95a2\u4e0e\u3068\u6ce1\u6cab\u7d30\u80de\u3001\u5225\u518aBioClinica 2013; 2\uff1a 22-7.<\/p>\n

11. \u7560\u5c71\u91d1\u592a\u3001\u5c71\u4e0b\u3000\u7be4\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u30fb\u8840\u6813\u75c7\u75c5\u614b\u3068\u81ea\u7136\u708e\u75c7\u306e\u4ecb\u5728\u30b7\u30b9\u30c6\u30e0\u3068\u3057\u3066\u306e\u51dd\u56fa\u7dda\u6eb6\u30fb\u8840\u5c0f\u677f\u7cfb\u3001Thrombosis Medicine 2013; 3: 51-5.<\/p>\n

12. \u6d45\u7530\u7950\u58eb\u90ce\u3001\u7560\u5c71\u91d1\u592a\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u5c71\u4e0b\u3000\u7be4\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u52d5\u8108\u8840\u6813\u306e\u96fb\u5b50\u9855\u5fae\u93e1\u50cf\u3068\u30a2\u30c6\u30ed\u30fc\u30e0\u8840\u6813\u75c7\u306e\u767a\u75c7\u6a5f\u5e8f\u3000\u75c5\u7406\u3068\u81e8\u5e8a 2013; 31: 1033-9.<\/p>\n

13. \u7560\u5c71\u91d1\u592a\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u7279\u96c6\u3000\u52d5\u8108\u786c\u5316\u306e\u3059\u3079\u3066\u3000\u52d5\u8108\u786c\u5316\u306e\u767a\u75c7\u30e1\u30ab\u30cb\u30ba\u30e0\uff1a\u708e\u75c7\u3068\u306e\u304b\u304b\u308f\u308a\u3000\u533b\u5b66\u306e\u3042\u3086\u307f\u30002013; 245: 1101-6.<\/p>\n

14. \u7560\u5c71\u91d1\u592a\uff1a\u7814\u7a76\u96c6\u4f1aMPM2013\u3001\u6570\u5b66\u3068\u73fe\u8c61\uff1a\u52d5\u8108\u786c\u5316\u306e\u6210\u308a\u7acb\u3061\u3068\u5408\u4f75\u75c7\u5831\u544a\u96c6 2013; pp30-40.<\/p>\n

15. \u5c71\u4e0b\u3000\u7be4\u3001\u4e45\u4e0b\u88d5\u53f8\u3001\u6d45\u7530\u7950\u58eb\u90ce\uff1a\u52d5\u8108\u786c\u5316\u306e\u753b\u50cf\u8a3a\u65ad\uff08FDG-PET\u3068\u8840\u6813\u5f62\u6210\u80fd\uff09\u3001Medical View Point 2013; 34: 3.<\/p>\n

\u25a0\u75c7\u4f8b\u5831\u544a<\/p>\n

1. Wakeda H, Hamasuna R, Asada Y, Kamoto T. Superior vena cava syndrome due to metastasis from urothelial cancer: A case report and literature review. Urol Ann 2013; 5: 291-3.<\/p>\n

2. \u76db\u53e3\u6df8\u9999\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u5c71\u4e0b\u7be4\u3001\u4f50\u85e4\u4fe1\u4e5f\u3001\u5927\u91ce\u62db\u4f38\u3001\u5fb3\u6e80\u8cb4\u5b50\u3001\u5cf0\u677e\u6620\u5b50\u3001\u795e\u7530\u4fee\u53f8\u3001\u6d45\u7530\u7950\u58eb\u90ce\u3001\u4e38\u585a\u6d69\u52a9\uff1a\u8853\u4e2d\u7d30\u80de\u8a3a\u3067\u8a3a\u65ad\u306b\u82e6\u616e\u3057\u305f\u677e\u679c\u4f53\u7d30\u80de\u816b\u306e\u4e00\u4f8b\u3000\u65e5\u672c\u81e8\u5e8a\u7d30\u80de\u5b66\u4f1a\u4e5d\u5dde\u9023\u5408\u4f1a\u96d1\u8a8c 2013; 4: 63-6.<\/p>\n

3. \u9bab\u5cf6\u76f4\u6a39\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u4e38\u585a\u6d69\u52a9\u3001\u677e\u6fa4\u8061\u53f2\u3001\u798f\u5cf6\u548c\u5b50\u3001\u5c71\u5185\u5247\u4e4b\u3001\u9bab\u5cf6\u6d69\u3001\u6d45\u7530\u7950\u58eb\u90ce: \u5916\u9670\u90e8\u81a8\u9686\u304b\u3089\u898b\u3064\u304b\u3063\u305faggressive angiomyxoma\u306e1\u4f8b.\u3000\u65e5\u672c\u5a66\u4eba\u79d1\u75c5\u7406\u5b66\u4f1a\u8a8c, 2013; 4: 41-3.<\/p>\n

4. \u983c\u7530\u9855\u8f9e\u3001\u4f50\u85e4\u52c7\u4e00\u90ce\u3001\u5927\u897f\u6df3\u4ec1\u3001\u9bab\u5cf6\u6d69\u3001\u7247\u5ca1\u5bdb\u7ae0: \u6f3f\u6db2\u6027\u5375\u5de3\u304c\u3093\u3068\u5375\u7ba1\u91c7\u4e0a\u76ae\u5185\u75c5\u5909\u3092\u8a8d\u3081\u305f1\u4f8b.\u3000\u65e5\u672c\u5a66\u4eba\u79d1\u75c5\u7406\u5b66\u4f1a\u8a8c, 2013; 4: 93-6.<\/p>\n<\/div>\n<\/article>\n<\/div>\n<\/section>\n

\n